Delving into the Latest Updates on Colecalciferol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(+)-vitamin D3, (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol, (5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol

+ [30]

Target

VDR

Action

agonists

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseInfectious DiseasesUrogenital Diseases+ [2]

Active Indication

Vitamin D DeficiencyHypoparathyroidismLower urinary tract infectious disease+ [2]

Inactive Indication

Chronic heart failureCrohn DiseaseDiabetes Mellitus, Type 2+ [6]

Originator Organization

Abiogen Pharma SpA

Active Organization

Galephar Pharmaceutical Research, Inc.

Italfarmaco SpA

Zensun (Shanghai) Sci & Tech Co., Ltd.

+ [5]

Inactive Organization

University of AarhusAlvogen Korea Co., Ltd.Metabolic Technologies, Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

Canada (01 Jan 1985),

Hypoparathyroidism

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC27H44O

InChIKeyQYSXJUFSXHHAJI-YRZJJWOYSA-N

CAS Registry67-97-0

The goal of this clinical trial is to determine if the level of Anti-cyclic citrullinated peptide antibody (ACPA) is altered after taking curcumin, omega-3, and vitamin D supplements (COD) for 3 months. It will also determine the safety and tolerability of COD in the study population. This trial aims to answer the following questions: Does COD consumption lower the level of ACPA in the study participants? What side effects will participants have after taking COD? This pilot study will have an open label pre-post design and study participants will know that they are using each of the three supplements. Participants will: Take the combination of supplements following an evening meal, for 84 consecutive days. Visit the clinic/study team twice during the study duration on days 0 and 84 for checkups and tests. Keep a diary of study treatment consumption.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Manitoba

[+1]

NCT07006714

/ Not yet recruitingPhase 4IIT

Preoperative Single High-Dose Vitamin D for Correcting Deficiency in Hip and Knee Arthroplasty Patients-A Prospective Study

The purpose of this study is being conducted to determine whether correcting low levels of vitamin D with a single high-dose supplement reduces complications after the participant's primary TJA.

Start Date01 Aug 2025

Sponsor / Collaborator

University of Miami

CTRI/2025/05/086335

/ Not yet recruitingPhase 4

The effect of Intravenous Vitamin D3 on clinical outcome of stroke patients in ICU- a prospective randomised double blind study - nil

Start Date24 Jun 2025

Sponsor / Collaborator

Indira Gandhi Institute of Medical Sciences

100 Clinical Results associated with Colecalciferol

Login to view more data

100 Translational Medicine associated with Colecalciferol

Login to view more data

100 Patents (Medical) associated with Colecalciferol

Login to view more data

25,342

Literatures (Medical) associated with Colecalciferol

31 Dec 2025·Artificial Cells Nanomedicine and Biotechnology

Vitamin D3 loaded polycaprolactone nanoparticles enhance the expression of the antimicrobial peptide cathelicidin in macrophages

Article

Author: Dube, Admire ; Ahmed, Rami ; Khoza, Star ; Dlozi, Prince N.

Tuberculosis (TB), primarily caused by Mycobacterium tuberculosis, remains a global health burden. Current antibiotic treatments are limited by adverse effects, poor adherence, and drug resistance, necessitating new therapeutic approaches. Recent studies highlight the role of vitamin D3 (VD3) in enhancing host immune responses against the mycobacterium via cathelicidin (an antimicrobial peptide) and autophagy activation. In this study, VD3-loaded poly-ƹ-caprolactone (PCL) nanoparticles (NPs) were synthesized to enhance cathelicidin expression in macrophages. NPs containing cholecalciferol, calcifediol, and calcitriol were synthesized using an emulsification solvent-evaporation technique. Average sizes of synthesized NPs ranged from 304.7 to 458.7 nm, with polydispersity index (PDI) and zeta potential (ZP) ranging from 0.103 to 0.257 and -17.3 to -7.47 mV, respectively. Encapsulation efficiencies were 9.68%, 10.99%, and 19.28% for cholecalciferol, calcifediol, and calcitriol, respectively. VD3-encapsulated NPs stimulated a dose-dependent increase in cathelicidin expression in THP-1 macrophages. Encapsulated calcifediol and calcitriol (100 ng/ml) induced the expression of 243.46 ng/ml ± 4.55 ng/ml and 396.67 ng/ml ± 25.24 ng/ml of cathelicidin, respectively, which was significantly higher than that induced by the free drugs. These findings suggest that NP encapsulation may offer a more efficient approach to using vitamin D3 for inducing cathelicidin expression as a host-directed treatment for TB.

31 Dec 2025·ANNALS OF MEDICINE

TsR-0072 inhibits colorectal cancer progression through modulating lipid and vitamin D ₃ metabolic reprogramming and inactivating the Wnt/β-catenin signalling pathway

Article

Author: Zhu, Guang ; Qi, Qianyi ; Chen, Bairong ; Xu, Jing ; Jin, Kangfeng ; Wang, Feng ; Chen, Lin ; Wu, Jinran ; Bao, Hongyi

BACKGROUND:

tRNA-derived small RNAs (tsRNAs), newly developed non-coding RNAs with specialized biological features, are aberrantly expressed in the majority of malignancies. However, whether tsRNAs are involved in metabolic reprogramming of colorectal cancer (CRC) remains to be elucidated.

METHODS:

A novel tsRNA, tsRNA-Ser-3-0072 (tsR-0072), was screened from the tsRFun database and its expression was characterized by real-time quantitative PCR (qRT-PCR). CCK8, 5-ethynyl-2'-deoxyuridine (EdU), colony formation, transwell experiments and nude mice transplantation models were performed to assess CRC cell proliferation and metastasis in vitro and in vivo. The target genes of tsR-0072 were verified using a dual luciferase reporter assay, and enzyme-linked immunosorbent assay (ELISA), Western blotting, and qRT-PCR were employed to analyse the potential mechanisms of CRC.

RESULTS:

TsR-0072 was downregulated in CRC and was found to be associated with TNM stage, T stage, lymph node metastasis and the prognosis of CRC patients. Functional experiments revealed that tsR-0072 inhibited CRC growth and metastasis both in vivo and in vitro. Moreover, sterol O-acyltransferase 1 (SOAT1) and 25-hydroxyvitamin D₃-24-hydroxylase (CYP24A1) were identified as direct targets of tsR-0072. Mechanistic studies revealed that tsR-0072 arrested lipid metabolism by downregulating the expression of SOAT1, which inhibited the activity of sterol regulatory element-binding protein 1 (SREBP1), sterol regulatory element-binding protein 2 (SREBP2) and fatty acid synthase (FASN). In addition, tsR-0072 promoted vitamin D₃ metabolism by decreasing the expression of CYP24A1, thereby increasing 1α,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) secretion and vitamin D receptor (VDR) expression. Both lipid and vitamin D₃ metabolic reprogramming induced by tsR-0072 resulted in inhibition of CRC progression through inactivation of the Wnt/β-catenin signalling pathway.

CONCLUSIONS:

TsR-0072 acted as an anti-oncogene to modulate lipid and vitamin D₃ metabolic reprogramming, thereby impeding CRC progression. Consequently, it might be a potential therapeutic target to overcome metabolic disorders in tumours. This study provided a promising transfer RNA (tRNA)-oriented strategy for the treatment of CRC treatment.

31 Dec 2025·Environmental Pollutants and Bioavailability

Evaluating the influence of aquatic environmental hazard, polylactic acid microplastics, on Labeo rohita

Author: Al-Ghanim, Khalid A. ; Ali, Shafaqat ; Naeem, Adan ; Hussain, Syed Makhdoom ; Rashid, Eram ; Sarker, Pallab K.

This research sought to evaluate toxicity after intake of polylactic acid microplastics (PLA-MPs) on multiple parameters of Labeo rohita fingerlings, focusing on their growth, nutrient consumption, body composition, histopathol., hematol. and minerals status.Six test diets were formulated using sunflower meal (SFM) serving as the reference diet, incorporating different MPs concentrations: control (0%), 0.5%, 1%, 1.5%, 2% and 2.5% MPs.The formulated diets were administered to triplicate groups of 15 fish, with each fed at 5% weight (live wet) for 90 days duration.The outcomes revealed that the growth had significantly decreased in L. rohita fingerlings when exposed to PLA-MPs.Furthermore, the apparent nutrients digestibility reduced with the escalation in PLA-MPs levels.PLA-MP exposure led to substantial alterations in body composition, including enhanced body fat and reduced protein content.Furthermore, blood profile was also altered after the PLA-MPs exposure.Addnl., examination of gut histopathol. indicated an intensification in abnormalities in intestine at the 2.5% PLA-MPs concentrationThe diet having 2.5% MPs exhibited the min. body mineral compositionThis study suggests that exposure of PLA-MPs influenced the L. rohita health performance.

157

News (Medical) associated with Colecalciferol

04 Aug 2025

·www.globenewswire.com

New Way to Take Iron: IBSA Launches Innovative Orally Dissolving Film Supplement That’s Gentle on the Stomach and Easy to Take

WATFORD, United Kingdom, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A new generation of vitamin supplementation has arrived in the UK. IBSA, the Swiss-based pharmaceutical company, has launched a groundbreaking Iron Orodispersible Film (ODF), a thin, fast-dissolving supplement strip designed to deliver iron and folic acid without the need for water or swallowing tablets. At a time when up to a third of UK adults report difficulty swallowing pills¹, and many struggle with the gastrointestinal side effects of traditional iron supplements², IBSA Iron ODF offers a welcome solution. Using IBSA’s patented FilmTec® technology, this small, lemon-flavoured strip melts in the mouth quickly, delivering a precise dose of 30 mg iron (as ferric pyrophosphate) and 400 μg folic acid with minimal digestive discomfort.“I’ve been taking Iron supplements for over 10 years and tried so many types, tablets, liquids, you name it. They all made me feel sick with nausea and even vomiting. Since I started using the ODF Iron, I haven’t had any of those side effects, and I still get all the benefits. It’s made a huge difference to how I feel in the morning”. Emma, verified patient, Oxford. Unlike some iron tablets that can cause side effects such as nausea, constipation, or a metallic taste, IBSA Iron ODF uses ferric pyrophosphate, a gentler form of iron, alongside a minimalist ODF formulation. This form bypasses much of the digestive system, helping reduce irritation whilst maintaining comparable absorption to some Iron tablets². It’s also gluten-free, lactose-free, and vegan friendly and contains less than 1 kcal per film.Who is it for?IBSA Iron ODF is particularly suited to: Women during menstruation, pregnancy, or postpartum recoveryAthletes with higher iron needsPeople with gastrointestinal absorption issues (e.g. Crohn’s, coeliac disease)Anyone who dislikes or struggles to swallow tablets IBSA Iron ODF is part of a new range of oral film supplements now available from IBSA Care. The range also includes IBSA Vitamin D3 ODF, a 2000 IU supplement formulated to support bone and immune health in individuals with limited sun exposure, and IBSA Vitamin B12 ODF, designed for vegetarians, older adults, and anyone with reduced B12 absorption. All products are based on IBSA’s patented FilmTec® technology, combined with the company’s pharmaceutical expertise and dedication to innovation, providing convenient, high-quality supplements designed for real life. IBSA's ODF technology has been clinically evaluated for iron and vitamin D3 delivery. Studies demonstrate comparable absorption to market-leading capsule formats2 3, offering reassurance that these new supplements are as effective as they are easy to take.Visit www.ibsacare.co.uk for further information. Helen Pope, HPPR+44 (0)7879 818247, helen@helenpopepr.co.uk References1. Cook et al., 2024 – Dysphagia prevalence and patient preferences across Brazil, UK, China, and Indonesia. Healthcare (Basel), 12(18):1827. 2. Cupone et al., 2023 – Clinical evaluation of iron orodispersible film (ODF). Pharmaceutics, 15(6):1575. 3. Cupone et al., 2020 – Development and stability of vitamin D3 ODF formulation. Molecules, 25:5851. UKODF00003DOP: July 2025 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c5e03731-fb0b-409a-afd9-fc5e09a52f63

19 Jul 2025

·pharma.economictimes.indiatimes.com

185 drugs fail CDSCO quality Test; 4 samples flagged as Spurious

New Delhi: India’s drug regulator, the Central Drugs Standard Control Organization (CDSCO), identified 185 drug samples as ‘ Not of Standard Quality ’ (NSQ) and flagged four others as ‘spurious’ during its monthly quality review for June. Of the total NSQ samples, 55 were flagged by Central Drugs Laboratories , while the remaining 130 were reported by State Drugs Testing Laboratories. In addition, the CDSCO drug alert identified four spurious drug samples, including a Cefixime Tablet from Bihar, an ointment of Heparin Sodium and Benzyl Nicotinate from Delhi, and two samples of Rosuvastatin and Fenofibrate Tablets — Rosuvas F 10 and Rosuvas F 20—collected from Telangana. A drug is deemed spurious if it qualifies certain conditions detailed under Section 17-B of the Drugs and Cosmetics Act, 1940. Of the 55 samples flagged as NSQ by central testing laboratories includes Dextrose Injection manufactured by Tam-Bran Pharmaceuticals; Azithromycin Tablet by Apple Formulations; Paracetamol Intravenous Infusion by D.J. Laboratories Telmisartan Tablets by Healers Lab and 51 other samples. The 130 samples flagged by state laboratories includes several common medicines and supplements such as Paracetamol, Pantoprazole, Calcium , Vitamin D3 tablets and several other common drugs. The identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters and the term NSQ has been defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. However, according to the Health Ministry, “identification of drug samples as 'NSQ' does not warrant any concerns on the other drug products available in the market. The CDSCO routinely notifies ‘'NSQ ' and spurious medicines based on a monthly review undertaken by the central and state drug regulatory bodies to ensure that these drugs are removed from the market and enforce quality norms. By Abhijeet Singh ,

22 May 2025

·pharma.economictimes.indiatimes.com

Many MSME pharma firms making substandard drugs, CDSCO data shows

New Delhi: Many pharmaceutical companies in the micro, small and medium enterprise (MSME) sector are manufacturing substandard drugs , according to the data by India's drug regulator, the Central Drugs Standard Control Organisation ( CDSCO ). According to the data for April, most of these companies are making drugs that failed safety standards and have been found to be sub- standard quality. As part of the continuous regulatory surveillance , drug samples are picked from sales and distribution points and analysed at various government run laboratories. According to the drug regulatory authority, in April about 60 samples failed to meet the quality standards and have been declared as Not of Standard Quality (NSQ) Drugs . Samples which failed tests are carboxymethylcellulose sodium eye drops, an eye lubricant, also known as artificial tears, bupivacaine hydrochloride injection, a local anaesthetic, calcium carbonate and vitamin D3 tablets, among others. Interestingly, they have been manufactured at lesser known pharma companies like Gidsha Pharmaceuticals in Gujarat, Martin and Brown Biosciences in Solan, Himachal Pradesh, Sai Parenterals in Hyderabad, Nestor Pharmaceuticals, Faridabad, among others. These companies could not be contacted immediately. "This has been the trend for some time now. Most of these MSME are found to be manufacturing drugs which are not of standard quality. That is the reason the health ministry came out with a notification which outlines standards for the pharma companies," said a person with knowledge of the matter. Earlier in 2023, over 65 per cent of MSME enterprises were found to be manufacturing drugs that were not of standard quality (NSQ) during risk-based inspections (RBI) of pharma companies. "Of the total MSME units inspected, 30 per cent were issued stop production orders (SPO), while samples of 68% MSME companies have failed. This is alarming," the person said. The CDSCO and state drug inspectors have been conducting these inspections as part of a massive nationwide crackdown on spurious and substandard medicines. This followed a controversy over alleged Made-in-India cough syrups being responsible for the deaths of children in The Gambia. The CDSCO has found that these companies have issues related to infrastructure, quality management systems and product manufacturing process knowledge. "There has been a strong correlation between NSQ and the condition of manufacturing set up. Monthly NSQ data shows repeat failures for a company with the same product with multiple companies month on month," another person said. India's drug regulator had earlier pointed to an urgent need to review the current GMP regulations and Quality Management Systems being followed by pharmaceutical companies during the RBI. By Teena Thacker ,

100 Deals associated with Colecalciferol

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00188	Colecalciferol	A11CC05	DB00169

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Vitamin D Deficiency	China	Jiangsu Wuzhong Medicine Group Co., Ltd.	01 Jan 1987
Hypoparathyroidism	Canada	-	01 Jan 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoporosis, Postmenopausal	Phase 3	South Korea	Alvogen Korea Co., Ltd.	01 Dec 2011
Chronic heart failure	Phase 3	Italy	Abiogen Pharma SpA	01 Nov 2011
Hypercalcemia	Phase 3	Denmark	University of Aarhus	01 May 2008
Hyperparathyroidism, Primary	Phase 3	Denmark	University of Aarhus	01 May 2008
Crohn Disease	Phase 3	Denmark	University of Aarhus	01 Sep 2005
Lower urinary tract infectious disease	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	08 May 2021
Osteoporosis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Rheumatoid Arthritis	Phase 2	Denmark	University of Aarhus	01 Dec 2015
Diabetes Mellitus, Type 2	Phase 2	Denmark	University of Aarhus	01 Dec 2008
Complicated urinary tract infection	Phase 2	China	Zensun (Shanghai) Sci & Tech Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04621500 (VitD/RNA-seq, CTgov)	Phase 2	Vitamin D Deficiency \| Prostatic Cancer	60	Allostatic Load+cholecalciferol	qrlyojpaey = jkawqzggdc bbyaaqyejh (nyoshqdila, lronfphxyj - uzhqdwammq) View more	-	04 Jul 2025
NCT01463813 (Finnish Vitamin D Trial, Pubmed \| J Gerontol A Biol Sci Med Sci)	Not Applicable	Well Aging serum 25-hydroxyvitamin D concentration	2,492	Vitamin D3 (Placebo)	cgvjlcrttl(irlhrhpurg) = without statistically significant differences in the event rates between the three arms doumtvyquv (wqbygcvzjq ) View more	Negative	10 Jun 2025
				Vitamin D3 1600 IU/day
NCT04428359 (Pubmed \| Health Sci Rep)	Not Applicable	Warts	61	Intralesional MMR Vaccine	bezddaykws(esfyiahwao) = rare with MMR wzqthctvkj (stfzuupeeh ) View more	Positive	01 May 2025
				Intralesional Vitamin D3
NCT02224144 (CTgov)	Phase 2	Bone Diseases, Metabolic \| Vascular Calcification \| Kidney Failure, Chronic ... View more	61	Calcitriol+Vitamin D3 (Vitamin D3 Plus Calcitriol)	vjznjnenxx(scxyhfojwq) = wwydgxhldi elhtczbhaw (goezrtpyku, 0.54) View more	-	07 Mar 2025
				Placebo+Vitamin D3 (Vitamin D3 Plus Placebo)	vjznjnenxx(scxyhfojwq) = juqhmnpquk elhtczbhaw (goezrtpyku, 0.46) View more
NCT01748448 (ViDMe, CTgov)	Phase 3	Melanoma, Cutaneous Malignant	436	Vitamin D (Vitamin D)	hlvpiawuix = jhinbhthnh mlwmgltjnh (gichxrtxgx, aecanorqxx - oexuyuegix) View more	-	17 Feb 2025
				Placebo: Oil (Placebo: Oil)	hlvpiawuix = zdxljtsoky mlwmgltjnh (gichxrtxgx, rnfqhcgedl - hmwynutnfe) View more
NCT04780061 (CTgov)	Phase 3	COVID-19	90	Vitamin C/Zinc+Vitamin D3 (Treatment)	umhnwxmlmc(yfmairbbeb) = ozulqmumsz ijrofdkwmg (cegepeubwm, 226.6) View more	-	19 Sep 2024
				Medium Chain Triglyceride Oil (Control)	umhnwxmlmc(yfmairbbeb) = iongzmixrh ijrofdkwmg (cegepeubwm, 220.7) View more
NCT01443728 (CTgov)	Phase 2	Asthma \| Vitamin D Deficiency \| Acute Chest Syndrome ... View more	70	Vitamin D3 (Vitamin D3 100,000 IU)	vhwfprypcr(ioijvhcrmh) = kjsdjueuvk bdjpqdkhfu (gjahnrwhpt, 0.35) View more	-	09 Aug 2024
				Vitamin D3 (Vitamin D3 12,000 IU)	vhwfprypcr(ioijvhcrmh) = uuddjmhlza bdjpqdkhfu (gjahnrwhpt, 0.35) View more
NCT01169259 (VITAL, ENDO2024)	Phase 3	Diabetes Mellitus, Type 2	-	Vitamin D 2000 IU/d	vcygskpxja(cbqircbkxq) = zafwertcvm qvlinilxit (qkqbhymcxo )	Negative	01 Jun 2024
				Vitamin D (Placebo)	vcygskpxja(cbqircbkxq) = yvwapwsgzj qvlinilxit (qkqbhymcxo )
NCT02757872 (CTgov)	Phase 3	Kidney Diseases \| Hypertension	2,232	Omega-3 Fatty acids+Vitamin D3 (Vitamin D and Omega-3 Fatty Acids)	wanqaenkvm = zuxftdsvrv enqoigoxyj (lusnueheko, bdhflonzqy - vnmyjvmykq) View more	-	31 May 2024
				Fish oil placebo+Vitamin D3 (Vitamin D and Omega-3 Fatty Acid Placebo)	wanqaenkvm = iaaeohppib enqoigoxyj (lusnueheko, miiulcqcii - cgeioyajao) View more
NCT01169259 (VITAL, Pubmed \| Clin Infect Dis) Manual	Phase 3	vitamin D deficiency	-	vitamin D3 2000 IU/day	jmnkquaqhb(dqhcopuimv): OR = 0.96 (95% CI, 0.86 - 1.06)	Negative	15 May 2024
				Vitamin D (Placebo)